Strategic Acquisition Foresight Diagnostics was acquired by Natera in December 2025 for a substantial upfront value with milestone-based earn-out potential, signaling strong integration opportunities for combined ctDNA and MRD workflows and potential access to Natera’s broader customer base.

MRD Leadership The company focuses on high-sensitivity ctDNA assays and minimal residual disease measurement with its CLARITY PV detection method, presenting a compelling upsell for labs and oncologists seeking superior MRD monitoring capabilities.

Clinical Validation Recent and ongoing clinical presentations and trials, including PRECISE-HL and IASLC World Conference data, create opportunities to position CLARITY as part of evidence-backed diagnostic portfolios in lymphoma and lung cancer workflows.

Strategic Partnerships Collaborations with Qiagen to develop kit-based CLARITY assays indicate a channel-driven sales path and potential for co-marketing agreements, expandability into instrument-agnostic or at-home lab settings, and broader distribution.

Growth and Reach With a CLIA lab in Boulder and a revenue range of 50–100 million alongside a Series B in 2024, there is investor confidence and capacity for expanding sales targets, geographic expansion, and new assay offerings through cross-sell to Natera’s existing customers.